



**At the leading edge
of biotechnology
and health care**

Annual General Meeting 2015



Disclosure

All statements and other information contained in this document related to PlantForm Corporation as well as other statements about anticipated future events or results, constitute forward-looking statements. Forward-looking statements often, but not always, are identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “forecast”, “project”, “likely”, “potential”, “targeted” and “possible” and statements that an event or result “may”, “will”, “would”, “should”, “could” or “might” occur or be achieved and other similar expressions. Forward-looking statements are subject to known and unknown business and economic risks and uncertainties and other factors that could cause actual results of operations to differ materially from those expressed or implied by the forward-looking statements. Forward-looking statements are based on estimates and opinions of management at the date the statements are made. PlantForm Corporation does not undertake any obligation to update forward-looking statements even if circumstances or management’s estimates or opinions should change. For the reasons set forth above, investors should not place undue reliance on forward-looking statements. Investors are encouraged to consider their own risk tolerance and the risk involved in investing in the PlantForm Corporation. Investors should understand that investment in the Common Shares is not guaranteed, and investors could lose part or all of their investment. The decision to invest in the Common Shares should be based solely on the contents of the confidential information memorandum dated February 23, 2015 and the subscription agreement (collectively the “Subscription Documents”), each of which are provided to all investors. A list of risks related to the purchase of the Common Shares can be found in the confidential offering memorandum. These Subscription Documents each supersede all prior exchanges of information, whether oral or written. The Company has engaged Legacy Partners Wealth Strategies Inc. (“LPWS”) to act as its agent in distributing common shares of the PlantForm Corporation.



Presentation Overview

- 1. Corporate summary**
2. Annual report 2014-15
3. Going forward





Market Opportunity

- Pharmaceutical industry facing a diminished R&D pipeline:
 - ✓ Expensive to develop new drugs
 - ✓ Estimated cost to develop an original pharmaceutical is from USD 0.5 to 2 billion +
 - ✓ Diminished internal rate-of-returns
- Competition from generic manufacturers as original patents expire
- Governments looking to reduce drug benefit costs using biosimilar drugs






Value Proposition

**Monoclonal Antibody/Protein
Molecule Focus**

Low Production Costs

**Protected by
Long-Term Patents**

**Competitive Pricing Power
and Strong Margins**



**Fast Development
Timeline**

**PlantForm has a focused business strategy around
low-cost production of biosimilars to take advantage
of the 'patent cliff' facing innovator drugs**



Strategy & Business Model

Leverage proprietary technology and low-cost plant-based manufacturing processes to produce biosimilars for the high-value biologics that are expected to go off-patent



Value Creation

Identify High-Value Biologics

- Screen biosimilar landscape to rank most attractive opportunities
- Select most promising candidates for development

Commercialize Applications

- Achieve platform proof of concept (as with biosimilar trastuzumab)
- Applicable to all antibodies (biosimilar and innovative)

Out-License Products to Partners

- Rank potential partners for desired attributes
- Optimal partnership timing is on completion of Phase I trial
- “Operating System” model serves many partners simultaneously
- Produce commercial returns and exits for investors



Competitive Advantage



- Developing high-value antibody and protein drugs using a low-cost, plant-based production system
- Tobacco – PlantForm’s bio-reactor – fast-growing, large leaf-to-ground space ratio
 - ✓ Drug gene is synthesised and inserted into the plants using an agrobacterium
 - ✓ Plant produces drug within 7-10 days of gene insertion
 - ✓ Growth, harvest, extraction and purification in an 8-week total cycle
- Patented-protected process used under licence from University of Guelph
- Capable of manufacturing drugs at only 10% of conventional, fermentation-based pharmaceutical manufacturing



Pipeline Projects (Biosimilars)

Pipeline Drugs	Potential Total Market Size (USD)	Market Entry
Biosimilar Herceptin [®]	>\$7.0 billion	2019
Biosimilar Humira [®]	>\$13.0 billion	2019-2022
Niche biosimilar drugs	>\$0.5 billion each	



Pipeline Projects (Innovator)

Pipeline Drugs	Funding Partners	Market Objective
Anti-Ebola antibodies	IRAP	Current/potential revenue streams - & - Sales/ Government stockpiling opportunities
Anti-HIV antibodies	CHTD-IRAP	
Anti-bioterrorism drugs	DRDC	



Assets – Proprietary Patents

Four families of patents

**Core platform
technology**
to 2028

**Biosimilar trastuzumab
manufacturing process**
to 2031

**Very high yield
production system**
to 2031

**Innovative drug
candidate**
to 2029



Assets – Proprietary Patents

Four families of patents

**Core platform
technology**

to 2028

Australian patent issued

**Biosimilar trastuzumab
manufacturing process**

to 2031

**Very high yield
production system**

to 2031

**Innovative drug
candidate**

to 2029

2 USA patents issued



The PlantForm Team

Management


- Don Stewart, PhD, CEO
- Craig Binnie, PhD, VP R&D
- David Cayea, COO
- Chris Hall, PhD, CSO
- Ron Hosking, CFO

Laboratory

- PhD: 6
- MSc: 4
- BSc/College: 3

Operations

- Communications Director
- Project Manager
- QA Manager
- Board Administration





Presentation Overview

1. Corporate summary
- 2. Annual report 2014-15**
3. Going forward





Key Industry Milestones

FDA

- First U.S. biosimilar: Sandoz's Zarxio (biosimilar Neupogen®)
 - 5 May, 2015: FDA approval
 - 21 July, 2015: US Court ruling cleared the way for Zarxio market launch on 2 September, 2015.

Heath Canada

- Celltrion's Remsima (biosimilar Remicade®)
 - 18 Sept., 2014: Celltrion reports first sale of Remsima in Canada

PBVAB Conference

- International Conference, Lausanne, Switzerland, 8-20 June, 2015:
 - “Monoclonal antibody production in plants offers rapid production advantages in comparison to mammalian cells, with at least equivalent product safety, purity and potency.”

Julian Ma (St. George's University of London, London, UK), Conference Chair



PlantForm Milestones 2014-15

Achievements

- Financing
 - Secured > \$1 million in financing
 - Advancing financing opportunities in Canada with LPWS
 - Advancing financing opportunities in Europe with Ruffena
 - Advancing financing opportunities in Asia with a syndicate
- Biosimilar Herceptin®
 - Initiated manufacturing with Fraunhofer CMB
 - Project will advance on next financing (\$2 million)
- Joint Venture in Brazil
 - Initial financing commitment from Financiadora de Estudos e Projetos (FINEP), Brazil for Brazilian activities
 - Initiated work program
 - Advancing additional financing opportunities



PlantForm Milestones 2014-15

- Platform Technology
 - Internal R&D improved glycosylation and production rates
 - Externally funded (NSERC) collaborative technology improvement projects established with Ryerson University, University of Calgary and University of Guelph
- Grants
 - Secured additional \$0.5 million for HIV/AIDS project from CHTD-IRAP
 - Secured financing for early-stage development of anti-Ebola Sudan antibody drugs in collaboration with USAMRIID, USA
- Contracts
 - Secured \$0.8 million funding with DRDC-Suffield, Canada for countermeasures to bioterrorism project
 - Secured project funding with major USA biotechnology company to evaluate *vivoXPRESS*[™] production platform



PlantForm Milestones 2014-15

Challenges

- iBio lawsuit
 - In late 2014, PlantForm received notice of a lawsuit by iBio, Inc. alleging tortious interference of iBio's contract with a third-party contract manufacturer, misappropriation of trade secrets and other unfair competition. PlantForm has vigorously denied these claims and filed a counterclaim against iBio.
 - On 14 May, 2015 iBio and PlantForm agreed to a mediated settlement.
- Biosimilar Herceptin®
 - Scale up and manufacturing campaign at Fraunhofer CMB on hold due to required manufacturing site change
 - Closing Series A financing for project is awaiting conclusion of due diligence evaluation



Financial Objectives 2014-15

Financial objectives		Status	
1	Secure biosimilar Herceptin® project funding	Canada – LPWS finders agreement, initial investment secured, others ongoing Asia – Investment Term Sheet exchanged Europe – Ruffena finders agreement	In process
2	Secure funds from Brazil for PlantPraxis Joint Venture	FINEP funding commitment	✓
3	Secure contract research agreement(s)	Agreements with DRDC, IRAP/ Gates, IRAP-Ebola and a major USA biotechnology company	✓




Technical Objectives 2014-15

Technical objectives		Status	
1	Conduct animal toxicity studies with biosimilar Herceptin®	Delayed, pending financing	In process
2	Initiate technology transfer to PharmaPraxis in Brazil	Tech transfer initiated, equipment purchase ongoing	✓
3	Advance sialation pathway research program with Ryerson University	Agreement placed, funding secured from NSERC, positive data from research studies	✓



Presentation Overview

1. Corporate summary
2. Annual report 2014-15
3. **Going forward**





Objectives for 2015-16

Financing Objectives

- 1 Secure equity investment for biosimilar Herceptin[®] project
- 2 Secure non-dilutive funding for Ebola project

Technical Objectives

- 1 Conduct Phase I manufacturing of biosimilar Herceptin[®]
- 2 Conduct animal toxicity studies of biosimilar Herceptin[®]
- 3 Establish *vivoXPRESS*[™] technology in Rio, Brazil
- 4 Conduct animal study with HIV/AIDS drug candidates
- 5 Expand patent portfolio



Why Invest in PlantForm?

- PlantForm's technology will fight some of the most prevalent and devastating global diseases:
 - Breast Cancer, HIV/AIDS, Ebola
- Disruptive, leading-edge, patent-protected plant technology is a cost-effective alternative to traditional production systems
 - Production cost reduction down to 10% of the cost of name-brand drugs; faster production
- Global biosimilar market is expanding rapidly as brand-name drug patents expire, creating an extraordinary business growth opportunity
- No Phase II clinical trials and reduced Phase III clinical trials
- Significant interest from government and non-governmental organizations



Exit Opportunities

PlantForm has identified two potential liquidity events for investors

OPTION 1: On completion of Phase I Clinical Trials

- Execute a private transaction to pharmaceutical or other company
- List the corporation on a public market

OPTION 2: On completion of Phase III Clinical Trial

- Execute a private transaction to pharmaceutical or other company
- Form strategic alliance with global and/or regional pharmaceutical distribution companies
- List the corporation on a public market



Thank You

Making Life-Saving Medicine More Affordable

- We are pleased to invite you to lunch at the Delta Hotel
- A tour of our labs and growth facilities is arranged for around 2 p.m. for interested parties

